HLS Stock Overview
A specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HLS Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.20 |
| 52 Week High | CA$5.48 |
| 52 Week Low | CA$3.00 |
| Beta | 1.04 |
| 11 Month Change | -0.93% |
| 3 Month Change | -6.84% |
| 1 Year Change | -38.46% |
| 33 Year Change | -82.22% |
| 5 Year Change | -78.75% |
| Change since IPO | -72.39% |
Recent News & Updates
Recent updates
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22HLS Therapeutics (TSE:HLS) Will Pay A Dividend Of CA$0.05
Nov 29Shareholder Returns
| HLS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -1.8% | -1.9% | 1.0% |
| 1Y | -38.5% | -12.9% | 18.6% |
Return vs Industry: HLS underperformed the Canadian Pharmaceuticals industry which returned -8.7% over the past year.
Return vs Market: HLS underperformed the Canadian Market which returned 18.7% over the past year.
Price Volatility
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.1% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: HLS has not had significant price volatility in the past 3 months.
Volatility Over Time: HLS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 91 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels.
HLS Therapeutics Inc. Fundamentals Summary
| HLS fundamental statistics | |
|---|---|
| Market cap | CA$104.92m |
| Earnings (TTM) | -CA$32.67m |
| Revenue (TTM) | CA$79.88m |
1.3x
P/S Ratio-3.1x
P/E RatioIs HLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLS income statement (TTM) | |
|---|---|
| Revenue | US$58.89m |
| Cost of Revenue | US$14.23m |
| Gross Profit | US$44.67m |
| Other Expenses | US$68.76m |
| Earnings | -US$24.09m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 75.84% |
| Net Profit Margin | -40.91% |
| Debt/Equity Ratio | 99.7% |
How did HLS perform over the long term?
See historical performance and comparison